Abstract Two cases of zinc deficiency in breastfed neonates were investigated where zinc levels in the mothers' milk were reduced by more than 75 % compared to normal. The objective of this study was to find the molecular basis of the maternal zinc deficiency condition. Significant reductions in mRNA expression and protein levels of the zinc transporters SLC30A5 and SLC30A6 were found in maternal tissue, suggesting a causal link to the zinc-deficient milk. Novel splice variants of the SLC30A6 transcript were detected. No modifications were found in coding regions, or in transcription binding sites of promoter regions or in 5 0 and 3 0 untranslated regions of both transporters in lymphoblasts and fibroblasts isolated from both mothers. Altered DNA methylation in SLC30A5 at two CpG sites was detected and may account for the reduced levels of SLC30A5 mRNA and protein in lymphoblasts. Reduced SLC30A6 mRNA and protein levels in lymphoblasts may be secondary to reduced SLC30A5 expression, as they function as a heterodimer in zinc transport. In conclusion, two cases of zinc deficiency are linked to low levels of the SLC30A5 and SLC30A6 zinc transporters. These two zinc transporters have not been previously associated with zinc deficiency in milk.
Introduction
The most frequently occurring form of zinc deficiency is caused by nutritional insufficiency. In some cases however, zinc deficiency is found in breastfed babies, who present with symptoms characteristic of nutritional zinc deficiency, including dermatitis, diarrhoea, alopecia, loss of appetite, impaired immune function and neuropsychiatric changes (Aggett et al. 1980; Prasad 1985) . This form of zinc deficiency is a consequence of reduced levels of zinc in the maternal milk and has been reported in preterm babies (27-to 33-week gestation) (Aggett et al. 1980; Connors et al. 1983; Heinen et al. 1995; Parker et al. 1982; Weymouth et al. 1982; Zimmerman et al. 1982) and less commonly in full-term babies (Bye et al. 1985; Glover and Atherton 1988; Khoshoo et al. 1992; Stevens and Lubitz 1998) .
& M. Leigh Ackland leigha@deakin.edu.au Pedigree analysis indicates that the condition is inherited (Sharma et al. 1988) . Zinc levels in the maternal milk of zinc-deficient breastfed babies were \40 % that of normal milk at matched weeks of lactation (Weymouth et al. 1982; Zimmerman et al. 1982) . Maternal zinc deficiency was not responsible for the low zinc levels in breast milk (Weymouth et al. 1982; Zimmerman et al. 1982) . Zinc deficiency caused by reduced zinc levels in the milk is associated with defects in SLC30A2 (ZnT2). A missense mutation that substituted a conserved histidine, at amino acid 54, with arginine (H54R) was reported (Chowanadisai et al. 2006) . The production of zinc-deficient milk was also linked to a glycine to arginine substitution (G87R) (Lasry et al. 2012) . Two novel missense mutations in the SLC30A2 (ZnT2) genes were reported in a Japanese mother with milk zinc levels reduced below 90 % of normal (Itsumura et al. 2013 ).
An inherited disorder of mice with similar phenotype to the human condition of reduced secretion of zinc into milk has been described (Piletz and Ganschow 1978) . Newborn pups that were nursed on 'lethal milk', homozygous mutant dams (lm/ lm), developed dermatitis, alopecia and showed stunted growth, leading to death within a week and a defect in the secretion of zinc from the mammary gland, were demonstrated (Ackland and Mercer 1992; Lee et al. 1992) . A nonsense mutation at arginine codon 297 in the Slc30a4 (ZnT4) zinc transporter, causing premature protein termination, was associated with the mouse disorder (Huang and Gitschier 1997) .
A study of the human orthologue (SLC30A4) of the murine Slc30a4 gene in two mothers with zinc-deficient milk, including sequence analysis of cDNA, real-time PCR and Western blot analysis, showed no differences between patient and normal control cells, which concluded that unlike the mouse disorder, defects in SLC30A4 were not responsible for the human disorder of reduced secretion of zinc into milk (Michalczyk et al. 2003) . In these patients, it is likely, therefore, that the maternal mammary gland defect in zinc secretion is different from the 'lethal milk' mouse model and that other candidate SLC30A transporters may underlie the mammary zinc transport defect. In our study, we sequenced SLC30A2 to detect mutations associated with these two unrelated mothers and investigated whether modifications to other SLC30A zinc exporters underlie this mammary gland disorder.
Materials and methods

Case histories
The following clinical presentation of two cases of zinc deficiency has previously been reported (Michalczyk et al. 2003) . Infant 1 was born premature at 36 weeks and was breastfed for three months. A red, necrolytic rash developed at 2 months of age (Fig. 1a, b) . Zinc deficiency was confirmed at 3 months post-partum by tests showing zinc blood levels of 4.5 lmol/l (0.29 lg/ml) (reference range 10.3-18.1 lmol/l; 0.67-1.18 lg/ml). The level of breast milk zinc from the mother of Infant 1 (Mother 1) was 0.29 lg/ml, which was less than one-quarter that of the normal zinc level (1.35 lg/ml) at the corresponding stage of lactation. Treatment of the infant with zinc (50 mg/day) resulted in a dramatic improvement in the rash within 3 days. Infant 2 was born premature at 37-week gestation and developed dermatitis affecting the face and perioral skin, with scalp scale and similar symptoms as that of Infant 1. The maternal milk zinc level (Mother 2) at 7 months was 0.2 lg/ml, which was considerably less than the normal zinc level (0.85 lg/ml). On commencing treatment with zinc (50 mg/day), the rash cleared in 3 days Fig. 1 Zinc-deficient Infant 1 born at 37 weeks gestation, showing necrolytic rash at extremities with blistering and desquamation (a) and (b) and hair started to grow fully. It is interesting to note that both mothers who produced zinc-deficient milk had no clinical symptoms of zinc deficiency themselves.
Sample collection and cell culture
Ethical approval for the collection of blood and skin biopsies was obtained from Deakin University, Melbourne, Australia (EC32-2000) , and the Royal Children's Hospital, Parkville, Australia (ERC 2025B). Fibroblast and lymphoblast cell lines from patients (Mother 1 and Mother 2) and respective healthy controls (three lymphoblast and three fibroblast lines) were established as previously described (Michalczyk et al. 2003) . The human epithelial breast cell line PMC42-LA, a variant of PMC42 cell line, originally derived from a pleural effusion (Whitehead et al. 1983) . Normal resting breast tissue (BT) was obtained from breast biopsies performed for diagnosis of breast disease.
Tissue non-specific alkaline phosphatase assay (TNAP) Fibroblast and lymphoblast from patients and pooled controls, PMC42-LA and BT, were collected for tissue nonspecific alkaline phosphatase (TNAP) activity. Collected pellets were lysed using ALP lysis buffer (10 mM Tris-HCL, pH 7.5, 0.5 mM MgCl 2 , 0.1 % Triton-X 100). Twenty micrograms of total cellular proteins was pre-incubated in lysis buffer for 10 min at room temperature. A 100 ll volume of substrate solution (2 mg/ml p-nitrophenyl phosphate in 1 M diethanolamine buffer, pH 9.8, containing 0.5 mM MgCl 2 ) (Sigma-Aldrich; Sydney, Australia) was added. After 10-min incubation at room temperature, p-nitrophenol, released by TNAP, was measured at 405 nm absorbance. Shrimp ALP (Roche Applied Sciences, Germany) was used as a standard.
DNA and total RNA isolation DNA was isolated from patient and pooled control fibroblast and lymphoblast cells using the Wizard Ò Genomic DNA Purification Kit (Promega) following the manufacturer's instructions. DNA concentrations were checked on a nanospec (Nanodrop 1000, Thermo Scientific) at wavelengths of 260/280 nm.
Total RNA was extracted from patient and pooled control fibroblast and lymphoblast cells using a Qiagen RNeasy Mini kit (Qiagen), following the manufacturer's instructions. Extracted RNA was purified using RNeasy kit. The purified RNA concentrations were estimated on a Nanospec (Nanodrop 1000, Thermo Scientific) at wavelengths of 260/280 nm.
Reverse transcription
Two micrograms of purified RNA from patient and control samples was reverse-transcribed using a High-Capacity cDNA reverse transcription kit (Applied Biosystems) per 20 ll reaction according to manufacturer's protocol. The reaction was carried out at 25°C for 10 min, 37°C for 120 min, 85°C for 5 min.
Real-time PCR
Amplification reactions were performed with 1 9 SYBR Green PCR Master Mix (Applied Biosystem, Warrington, UK), 3 lm of forward and reverse primers sequences (see Table 1 ) and 20 ng cDNA (RNA content prior to RT step). Samples were analysed in triplicate using GeneAmp 5700 Sequence Detection System (Applied Biosystems). An internal control of b-actin (see Table 1 for primer sequences) was used to normalize mRNA quantities and efficiency of reverse transcription. Amplification was performed for the ten known human zinc exporters (SLC30A1 to SLC30A10) from lymphoblasts and fibroblasts of patients and the control. Fluorescence produced by incorporation of SYBR green dye into double-stranded DNA was recorded after the elongation phase of each repetitive cycle. The specificity of each reaction was determined by analysis of the melting point dissociation curve generated at the end of each PCR. The threshold cycle value (C T ), defined as the cycle number when fluorescence levels exceed the threshold value, was calculated after each reaction. The C T value of b-actin was subtracted from the transporter C T value to produce DC T for each sample. The relative mRNA expression level of each sample was calculated using the equation 2 ÀDDC T , where DDC T is the difference between the control DC T and the patient's DC T . A t test was applied for statistical analysis of the results.
PCR and sequencing for coding and promoter regions
The coding regions of SLC30A2, SLC30A5 and SLC30A6, and promoter regions of SLC30A5 and SLC30A6 genes (4000 bp upstream) were amplified. PCR amplification was performed using 55 pmol of forward and reverse primers (Table 1) . They were then added to the PCR mixture consisting of 200 ng of DNA, 200 lm of each dNTP, PCR buffer, 1.5 mM MgCl 2 and 1 U Taq DNA polymerase (Sigma-Aldrich, Melbourne, Australia). The following PCR amplification conditions were applied: one cycle at 94°C for 3 min, 35 cycles at 94°C for 45 s, annealing temperature for 30 s, 72°C for 60 s, with final extension at 72°C for 10 min. PCR products were run on 1 % agarose 
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ACTCCAATGACCCCTCCTCT gel, and the right size bands were excised, purified and sent for sequencing to Monash Sequencing Centre, Melbourne.
Results were aligned to the original sequence using Sequencer software to identify any modifications.
Transcription binding motif analysis
Transcription binding motifs relevant to lactation and metal homoeostasis were identified manually by scanning the binding motif sequences through the promoter region for the two different transporters SLC30A5 and SLC30A6.
Western blots
Western blots were performed as previously described (Michalczyk et al. 2003) . Briefly, cell pellets were resuspended in 10 ml of lysis buffer and disrupted by passing through a 25-gauge needle 8-10 times followed by sonication on ice with a Microson Ultrasonic cell disruptor (Misonix Incorporated, NY, USA). Samples were then stored at -80°C until needed for analysis. Quantification of protein concentrations in cell lysates was performed using BSA protein assay kit (ThermoLab 
Primer names contain the name of the gene, and following abbreviations: Real real-time PCR primer, A-F primers for coding region sequencing, P promoter region primers, IE intron-exon primers Primers to ZnT4 were designed to GenBank sequence Accession No AF025409
Primers to ZnT1 were designed to GenBank sequence Accession No AF323590
Primers to ZnT2 were designed to GenBank sequence Accession No NM_032513
Primers to ZnT3 were designed to GenBank sequence Accession No U76010
Primers to ZnT5 were designed to GenBank sequence Accession No AF461760
Primers to ZnT6 were designed to GenBank sequence Accession No XM_059432 Primers to ZnT7 were designed to GenBank sequence Accession No AY094606
Primers to ZnT8 were designed to GenBank sequence Accession No AY117411
Primers to ZnT9 were designed to GenBank sequence Accession No BC016949
Primers to ZnT10 were designed to GenBank sequence Accession No AY117411
Primers to b-actin were designed to GenBank sequence Accession No E00829 System), following the manufacturer's instructions. Protein samples were prepared with 69 loading dye, and a Page Ruler TM Prestained Protein ladder (Fermentas) was used as a protein molecular weight marker. Sixty micrograms of each extract was fractionated by SDS-PAGE using Bio-Rad Mini Protein Gel system according to manufacturer's instructions. Proteins were transferred to nitrocellulose membranes (Pal Gelman) using a TransBlot Transfer Cell (Bio-Rad). Blots were incubated overnight at 4°C with monoclonal antibodies for SLC30A5 (Kambe et al. 2002) , diluted at 1:500 and SLC30A6 (Abnova mouse monoclonal #H00055676-M01) diluted at 1:250 in 1 % casein. Proteins were detected using 1:4000 dilution of horseradish peroxidaseconjugated sheep anti-mouse antibody and chemilluminescence detection kit (Roche Diagnostic) according to manufacturer's instructions. Images were captured using the Luminescent Image Analyser LAS-3000 (Fujifilm). Membranes were re-probed with b-actin antibody (diluted 1 in 2000) and processed as above. b-Actin and Ponceau S stains were used as controls. Densitometry, using Fuji Film Multi Gauge V3.0 computer software, was performed to quantify results, and ratios for protein levels were calculated relative to b-actin and Ponceau S stains.
Immunofluorescence
Fibroblasts from patients and controls and PMC42-LA cells were grown on 10-mm-diameter glass cover slips. BT blocks (1 cm 3 ) were immersed in OCT (Tissue Tek; Sydney, Australia) and frozen in liquid nitrogen for 3 min followed by sectioning (8-10 lm thickness) on gelatin (5 %)-coated slides using Leica CM1800 cryostat at between -17 and -20°C. At around 50 % confluency, coverslips with cells were rinsed with PBS (after 48 h for M17 treated chambers) and fixed in 4 % paraformaldehyde (Sigma-Aldrich; Sydney, Australia) for 5, 10 min for BT. After two washes with PBS, they were permeabilized with 0.1 % TX-100 (Sigma-Aldrich; Sydney, Australia) for 10 min (BT 5 % for 5 min) followed by blocking in 1 % BSA for 10 min (BT 3 % for 90 min). Cells were incubated overnight at 4°C with primary antibody diluted in 1 % BSA in PBS (SLC30A5 1/100, SLC30A6 1/75). After PBS washes, a secondary antibody Alexa Fluor 488 anti-mouse (Chemicon, Melbourne, Australia) diluted at 1:2000 was added and samples were incubated for 2 h at room temperature following by PBS washes. Coverslips were mounted on glass slides using ProLong Gold antifade reagent (Invitrogen; Melbourne, Australia). Confocal images were obtained using a Leica confocal microscope system TCS SP2 (Leica; Melbourne, Australia).
SLC30A5 and SLC30A6 pyrosequencing assay
Bisulphite pyrosequencing for DNA methylation analysis Bisulphite conversion of DNA was performed using EZ DNA Methylation Gold TM kit (Zymo Research) following the manufacturers' protocol. Briefly, 2 lg of genomic DNA was incubated with CT conversion reagent and incubated at the following temperatures; 98°C for 10 min, 64°C for 2.5 h and held at 4°C. DNA was then transferred to a spin column, washed, de-sulfonated, purified and finally eluted in a 10 ll volume.
Quantitative bisulphite pyrosequencing was used to determine the percentage methylation at individual CpG sites within the SLC30A5 and SLC30A6 promoter regions (NT_022184.15; 11212499-11212863). Briefly, 0.2 lg of bisulphite-treated DNA was added as a template in PCR using 12.5 ll Hot Star Taq mastermix (Qiagen), total volume 25 ll. Primer sequences and PCR conditions are given in Table 1 Biotin-labelled PCR products were captured with streptavidin Sepharose beads (GE Healthcare) and made single-stranded using a Pyrosequencing Vacuum Prep Tool (Qiagen). Sequencing primers were annealed to the single-stranded PCR product by heating to 80°C, followed by slow cooling. Pyrosequencing was then carried out on a Pyromark MD system. Cytosine methylation was quantified using proprietary PyroQ CpG 1.0.6 software. All PCR and pyrosequencing reaction were carried out in duplicate.
Assay validations were carried out to rule out any amplification bias of primers for methylated DNA and to assess assay reproducibility using methods described previously (White et al. 2006 ). All primers were found to be unbiased and data reproducible. Zero and 100 % methylated controls (Epitect control DNA, Qiagen, 59568) were routinely run alongside samples as internal controls.
Transcription factor binding site analysis
Transcription factor binding motifs relevant to lactation and metal homoeostasis were identified manually by scanning the promoter regions of the hZnT5 and hZnT6 genes for the binding motif sequences. To identify transcription factor binding motifs in the proximity of differentially methylated regions, genomic sequences were entered into MatInspector (Genomatix Software-http:// www.genomatix.de/en/index.html).
Statistical analysis
Data distributions were examined by the KolmogorovSmirnov test, and all data sets were normally distributed. Analysis of variance was used to examine methylation in patients versus controls and type of sample (lymphocytes versus fibroblasts), and the interaction between these fixed factors, at each individual CpG, and across the mean of the investigated CpGs in a given gene. A p value of \0.05 was considered statistically significant.
Results
Alkaline phosphatase activity was reduced in patient (Mother 1 and Mother 2) lymphoblasts Significantly reduced alkaline phosphatase activity was found in patient lymphoblast (Mother 1 and Mother 2) relative to control, pooled lymphoblasts (Fig. 2) . In fibroblasts, alkaline phosphatase levels were low, and no significant differences were detected between Mother 1, Mother 2 and pooled controls. Alkaline phosphatase activity was also detected in PMC42-LA cells and healthy BT.
mRNA expression levels of zinc transporters SLC30A5 and SLC30A6 were reduced in patient cells Expression levels of mRNA for all ten zinc exporters were measured in control, Mother 1 and Mother 2 cells using realtime PCR to detect changes in gene expression at transcription level. The control reactions lacking either primers and or template cDNA were negative for all analysed samples. The dissociation curve analysis of all PCR products revealed the single peaks of expected Tm (data not shown), confirming the specificity of all designed primers. The transcript levels of both SLC30A5 and SLC30A6 were significantly lower in lymphoblasts from Mother 1 (SLC30A5 0.26?/-0.12; SLC30A6 0.22?/-0.12) compared to healthy controls (SLC30A5 1?/-0.11 and SLC30A6 1?/-0.09) (p \ 0.05, t test; Fig. 3a) . In Mother 2, transcript levels of SLC30A5 were significantly lower in lymphoblasts (SLC30A5 0.35?/-0.08) compared to controls (SLC30A5 1?/-0.22), but there was no significant decrease in SLC30A6 (0.81?/-0.1) compared to controls (1?/-0.15) (p \ 0.05, t test) (Fig. 3a) . In fibroblasts from Mother 2, SLC30A5 and SLC30A6 transcript levels (SLC30A5 0.14?/-0.09; SLC30A6 0.4?/-0.11) were lower than in the control (SLC30A5 1?/-0.12 and SLC30A6 1?/-0.13; Fig. 3b ).
No differences in the mRNA expression levels of SLC30A1, SLC30A3, SLC30A4, SLC30A7, SLC30A9 and SLC30A10 of fibroblasts and lymphoblasts from Mother 1 and Mother 2 were found relative to corresponding control lymphoblast and fibroblast levels (p [ 0.05, t test; Fig. 3a,  b) . Neither SLC30A2 nor SLC30A8 mRNA transcripts were found in either fibroblasts or lymphoblasts from patients or controls. As the mammary gland was the source of the zinc-deficient milk, human BT was analysed for the presence of SLC30A5 and SLC30A6 transcripts. SLC30A6 transcripts were 48 times more abundant than SLC30A5 transcripts in normal mammary tissue (Fig. 3c ).
Sequence analysis of SLC30A2 from patients cells showed no gene mutations
As SLC30A2 has previously been linked with zinc-deficient patient's disorder, the open reading frame (ORF) of SLC30A2 was sequenced from lymphoblasts and fibroblasts of patients and corresponding controls. No nucleotide differences were seen between control, Mother 1 and Mother 2. Exon-intron splice variants were also analysed Fig. 2 Tissue non-specific alkaline phosphatase activity (TNAP). Total TNAP activity was detected at 405 nm wavelength, using p-nitrophenol as a substrate, in lymphoblasts, fibroblasts, PMC-42 mammary epithelial cells and breast tissue from both patients and control. Significant decreases were found in ALP activity in Mother 1 and Mother 2 lymphoblasts compared to control lymphoblasts. No differences were found between Mother 2 and control fibroblasts. Values represent mean of triplicates ± SEM, *p B 0.05 using nine different sets of primers (Table 1) corresponding to alternative splice sites for the SLC30A2 gene. No changes were observed for this transporter.
Sequence analysis of SLC30A5 and SLC30A6 cDNA showed no differences between patient and control cells
As there was reduced expression of SLC30A5 and SLC30A6 mRNA in fibroblast and lymphoblast cells from Mother 1 and Mother 2 compared to corresponding control cells, sequence analysis of cDNA was carried out to detect changes in the coding regions of these genes. In SLC30A5 (GenBank AF461760), two single nucleotide modifications at positions 1692 (C ? T) and 1800 (T ? A) from start codon were identified in some control and patient cells. These modifications did not alter the amino acid sequence of SLC30A5.
cDNA sequencing indicated no differences in the coding region of the SLC30A6 gene between patients and corresponding controls and in all lymphoblasts tested (both patients and controls). A full-length SLC30A6 message and a variant that was missing 43 nucleotides starting from position 216 (Fig. 4a) were found in lymphoblasts. Similarly, in all fibroblasts (patients and controls) two versions of SLC30A6 ORF were detected, one full length and another with 49 nucleotides missing from position 757 to 806 from start codon (Fig. 4b) . Sequence analysis was also performed at 5' and 3' untranslated regions (UTR) of SLC30A5 and SLC30A6 genes to find any changes present in the micro-RNA binding regions, but no differences were found between patient and control samples. Analysis of exon-intron structure of the SLC30A6 gene showed no differences between patient and control cells
To investigate whether the different SLC30A6 mRNA variants found in fibroblast and lymphoblast cells were due to alternate splicing, analysis of exon-intron structure of the gene was performed. The genomic sequence of SLC30A6 was obtained using BLASTn search of human genome available from GenBank. The SLC30A6 gene consists of 14 exons positioned on chromosomes 2p22.3. In lymphoblasts from both control and patients, two splice site variants were identified, a full-length message and a variant missing exon 4 (42 nucleotides). In the fibroblasts, a deletion of 48 nucleotides produced a truncated version of SLC30A6 mRNA (lacking exon 9), which coexisted with full-length message in these cells (Fig. 4c) .
Promoter analysis showed no differences between patient and control cells
To establish whether reduced levels of SLC30A5 or SLC30A6 were due to changes in the promoter regions of these genes, sequence analysis was carried out on the DNA up to 4000 base pairs upstream from the start codons of SLC30A5 and SLC30A6 (Fig. 5) . This region contained the following transcriptional regulatory elements: metal responsive element (MRE), STAT-5 (binding site for prolactin), TATA binding site, progesterone responsive element (PRE), gonadotrophin-responsive element (GRE) and insulin-responsive element (IRE). Point changes were observed at position -1155 (T?:), -1325 (G ? C) from the start codon and -545 (A ? G), -1735 (C ? T) in control and Mother 1 fibroblasts for SLC30A5 and SLC30A6, respectively, but did not affect the above-mentioned important transcription binding sites. 
Western blot analysis of SLC30A5 and SLC30A6 proteins showed reduced levels in patient cells
Western blot analysis was used to detect both SLC30A5 and SLC30A6 proteins in patient and control fibroblasts and lymphoblasts. A significant reduction in SLC30A5 and SLC30A6 proteins was observed for Mother 1 and Mother 2 lymphoblasts compared to control lymphoblasts (Fig. 6a,  b) . No changes were observed in fibroblasts for SLC30A6 protein expression. There was a significant reduction in SLC30A5 of Mother 2 fibroblasts. In lymphoblasts, the major band detected with the SLC30A5 antibody was 57 kDa, and a less intense band was seen at 55 kDa. For fibroblasts, a single band of 55 kDa was detected (Fig. 6a) . In lymphoblasts, no differences in SLC30A5 band sizes were seen between control and Mother 1 and Mother 2. Using the SLC30A6 antibody, two bands (55 and 57 kDa) with equal intensity were found in lymphoblasts and one band of 55 kDa in fibroblasts (Fig. 6b) . Lysates of the human breast carcinoma line PMC42-LA and human BT were tested for the presence of SLC30A5 and SLC30A6 proteins. The SLC30A5 antibody detected a weak band of size 57 kDa in PMC42-LA cell extracts while a strong band of 55 kDa was seen in BT (Fig. 6a) . The SLC30A6 antibody showed negligible amounts of SLC30A6 in the PMC42-LA cells and a strong band at 55 kDa in the BT (Fig. 6b) .
Intracellular localization of SLC30A5 and SLC30A6 was similar in patient and control cells
Confocal microscopy of fibroblasts from Mother 2 and control showed both SLC30A5 and SLC30A6 proteins to be localized in small vesicles throughout the cytoplasm (Fig. 7a, b, e, f) . Lymphoblasts also showed a similar distribution of SLC30A5 and SLC30A6 across the cytoplasm for patients and control (data not shown). A similar localization pattern for both zinc exporters was observed for PMC42 cells (Fig. 7c, g ). Sections of normal BT showed these transporters to be localized to specific regions of the tissue (Fig. 7d, h ).
DNA methylation patterns in lymphoblast were different between patients and control cells
SLC30A5 methylation
In lymphoblasts, CpG site 2 was found to be significantly less methylated in Mother 1 (4 %) and Mother 2 (4 %) compared with control samples (13 %; Fig. 8a ). In contrast, the reverse was seen in fibroblasts where Mother 2 methylation (52 %) was greater than in the control sample (38 %; Fig. 8b) . Methylation levels at all four sites were significantly higher in fibroblasts than lymphoblasts with the exception of CpG 1 and CpG 2 for the controls (Fig. 8a, b) .
SLC30A6 methylation
Methylation within the SLC30A6 gene was below the detectable levels in lymphoblast and fibroblast extracts from Mother 1, Mother 2 and control.
Discussion
In two affected women, low levels of zinc in the maternal milk combined with a response by the infants to zinc therapy indicated a defect in the maternal breast affecting secretion of zinc into milk. The observation that neither mother was suffering from zinc deficiency suggested that specific defects to zinc exporters in the mothers' BT were involved in this pathology. We found significant reductions in the TNAP activity of lymphoblasts from Mother 1 and Mother 2 relative to control lymphoblasts, consistent with zinc/zinc transporter activity required for the activity of TNAP (Suzuki et al. 2005) . In fibroblasts, TNAP activity was very low, consistent with other studies, which may have accounted for the lack of differences detected between the affected mothers and the control. The reduced TNAP in lymphoblasts is consistent with a reduced function of zinc export in the Mother 1 and Mother 2 cells relative to controls.
Missense mutations in SLC30A2 (ZnT2) have been reported to underlie cases of maternal defects of zinc secretion into milk, based on analysis of DNA extracted from mother's blood cells (Chowanadisai et al. 2006; Itsumura et al. 2013; Lasry et al. 2012) . In contrast to this, we found no detectable SLC30A2 mRNA in either lymphoblasts or fibroblasts from the two mothers who produced zinc-deficient milk. Sequence analysis of the ORF and exon-intron splice variants performed on patient and control samples from the two different cell types showed no changes, confirming that ZnT2 mutations were not responsible for this disorder. This raised the possibility that another molecular defect could be responsible for this condition. More than one member of the solute carrier family SLC30 may participate in the export of zinc into milk or there may be some redundancy amongst zinc transporters. This possibility is supported by observations that in mothers with mutations SLC30A2, some zinc was still present in the milk (Itsumura et al. 2013; Lasry et al. 2012 ).
Analysis of transcription of all 10 members of the mammalian SLC30A family showed that reduced levels of SLC30A5 mRNA were observed from fibroblasts and lymphoblasts of Mother 1 and Mother 2 compared to controls. A reduction in SLC30A6 transcripts was found in lymphoblasts and fibroblasts from Mother 1 but not in Mother 2, relative to control cells. Thus, defects in SLC30A5 and/or possibly SLC30A6 may underlie this disorder. We verified that both mRNA and proteins of these transporters were present in mammary tissue obtained from breast biopsies. Both SLC30A5 and SLC30A6 are located in the early secretory pathway (Huang and Gitschier 1997; Kambe 2011; Kambe et al. 2002; Kirschke and Huang 2003) ; thus, the SLC30A5 transporter may have a compatible role in sequestration of zinc into vesicles destined for secretion from mammary epithelial cells.
Cells from Mother 1, Mother 2 and controls contained alternative splice variants of SLC30A6. In lymphoblasts, in addition to the full-length transcript, a variant that lacked exon IV was present. In fibroblasts, a variant that lacked exon IX was detected in addition to the full-length transcript. Similar transcripts were found in extracts from both mothers and controls, indicating that the alternate splicing was not associated with the zinc-deficient phenotype. Splice variants of SLC30A5 differing have previously been found in Caco-2 cells, where one form contained all 17 exons, while the other lacked exons 1, 2, 4 and exons 15-17, (Jackson et al. 2007; Thornton et al. 2011 ). We did not detect splice variants of SLC30A5 in either lymphoblasts or fibroblasts.
Protein analysis indicated the presence of two isoforms for each of SLC30A5 and SLC30A6, corresponding to bands of 55 and 57 KDa in lymphoblasts. A 55 kDa band was the only band seen in fibroblasts, possibly due to the low abundance of the protein or alternatively our antibody only detected the full-length protein. A 55 kDa protein was also the single dominant band in the normal BT. The band sizes detected in both mothers and control were consistent with previously reported sizes of 55 and 57 and 60 kDa found in a range of human cells and tissues (Cragg 2008; Cragg et al. 2002; Kambe et al. 2002) . Identified bands of 55 kDa for the SLC30A6 protein corresponded with predicted size of the splice variant found in lymphoblasts where exon IV was missing 42 nucleotides (Fig. 4) .
The protein levels of SLC30A5 and SLC30A6 in lymphoblasts and fibroblasts were measured to establish if they were reduced, consistent with the mRNA data. In lymphoblasts from affected mothers, both SLC30A5 and SLC30A6 protein levels were reduced compared to the control. In fibroblasts however, the protein levels of SLC30A6 of cells from the affected mothers were no different from the control, for reasons that are not clear.
Both SLC30A6 mRNA and protein were more strongly expressed in normal BT than in isolated lymphoblasts and fibroblasts. The high expression of the transporters in normal breast cannot necessarily be attributed to a greater expression in mammary epithelial cells as the BT also contains many cell types including adipocytes, endothelial cells and smooth muscle cells. The mammary gland SLC30A6 mRNA levels were 48 times more expressed than SLC30A5. Assuming that SLC30A5/SLC30A6 also operates as a heterodimer in BT, then SLC30A6 may have additional functions in the mammary gland.
SLC30A5 and SLC30A6 form heterodimers, and this oligomerization is required for their zinc transport function (Kambe 2012) . SLC30A6 is not directly involved in zinc transport across the cell membrane as it does not have a zinc-binding site within the trans-membrane domain, but it may function as a modulator (Fukunaka et al. 2009 ). Thus, if one of either SLC30A5 or SLC30A6 protein is reduced, it may impair the function of the dimer in transporting zinc.
Both SLC30A5 and SLC30A6 possess a number of hormone-responsive elements including MRE, STAT-5, TATA binding site, PRE, GRE and IRE that strongly support a function for these transporters in mammary function in particular milk secretion which is controlled by prolactin. To detect changes in these binding sites of the promoter region of SLC30A5 and SLC30A6, promoter analysis was performed on sequences up to 4000-bp upstream of the translation start site. No changes were observed within these binding sites. miRNA analysis of the 3' region of these also revealed no changes.
Since CpG islands are present in the promoter region of the SLC30A5 and SLC30A6 genes, their expression may be regulated by promoter methylation. DNA methylation is involved in the down-regulation of members of the SLC family of transporters (Gonen et al. 2008; Hong et al. 2005; Kikuchi et al. 2006; Philibert et al. 2007; Zschocke et al. 2007 ). We investigated whether DNA methylation was associated with the altered levels of SLC30A5 and SLC30A6 transcripts found in cells from mothers producing zinc-deficient milk. In lymphoblasts, the methylation percentage of CpG site 1 in SLC30A5 was 6-7 times lower in Mothers 1 and 2 compared to the controls. However, due to the large variation in methylation within the control samples, the differences between Mothers 1 and 2 and controls were not significant. In the same cells, the methylation of SLC30A5 measured at CpG site 2 was 65 % lower in both Mother 1 and Mother 2 relative to control lymphoblasts. In fibroblasts, conversely, the percentage methylation at CpG site 2 was greater by 20 % in Mother 2 relative to the controls, and at CpG site 4 the methylation was 45 % lower in Mothers 2 compared to the controls.
Hypermethylation at the CpG site 2 in fibroblasts could be responsible for the lower level of expression of the SLC30A5 gene. In lymphoblasts, this CpG site was hypomethylated in affected mothers compared with controls, but expression levels were reduced at both the mRNA and protein levels. Although promoter DNA hypermethylation rather than hypomethylation is generally regarded as the suppressive epigenetic modification, this relationship is not always found and methylation may be suppress or enhance gene expression depending on cell type (Ions et al. 2013) . The difference in DNA methylation at CpG site 2 between affected mothers and controls could thus contribute to the differences in gene expression observed in both lymphoblasts and fibroblasts.
We detected no DNA methylation in the promoter region of SLC30A6 and thus can only conclude that differences in gene expression were not associated with DNA methylation in this region. We cannot exclude the possibility that DNA methylation in other regions of the SLC30A6 gene differed between the affected mothers and controls.
In summary, we report two cases of zinc deficiency in neonates caused by a defect in the transport of zinc into milk. Both cases are associated with significant reduction in both SLC30A5 and SLC30A6 mRNA and protein from cells from the mothers producing the zinc-deficient milk. Defects in these two transporters have not previously been implicated in neonatal zinc deficiency. Promoter analysis showing changes in methylation state to CpG site 2 in lymphoblasts, while not definitive, suggests that the expression of SLC30A5 may be modified by methylation and could potentially account for the reduced activity of SLC30A5 and low level of zinc in milk.
